Vor Biopharma upgraded to Buy at Stifel on telitacicept prospects

5 hours ago 2

• Healthcare
• On the Move

• Comments

Lisa-Blue/iStock via Getty Images

Vor Biopharma (NASDAQ:VOR) has been upgraded to Buy from Hold at Stifel as confidence in the company’s long-term potential has grown following prospects for its lead asset, telitacicept.

The shares of the company are up 13% so far today.

The

Recommended For You

More Trending News

See More »

About VOR Stock

• 1D
• 5D
• 1M
• 6M
• 1Y
• 5Y
• 10Y

Related Stocks

VOR	-

Trending Analysis

Trending News

1. Homepage
2. Politics
3. Vor Biopharma upgraded to Buy at Stifel on telitacicept prospects